Antoine Regnault

Lyon, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 66 publications

Psychometric Evidence for an Augmented PDAQ for Improved Measurement of Cognition-Related IADLs in Parkinson's Disease.

Psychometric Evidence for an Augmented PDAQ for Improved Measurement of Cognition-Related IADLs in Parkinson's Disease.

Journal: Movement disorders clinical practice

Published: December 11, 2025

A practical toolkit with recommendations for analysing and visualising patient-reported outcomes in early phase dose-finding oncology trials (OPTIMISE-AR).

A practical toolkit with recommendations for analysing and visualising patient-reported outcomes in early phase dose-finding oncology trials (OPTIMISE-AR).

Journal: The Lancet. Oncology

Published: October 26, 2025

Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial.

Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial.

Journal: Blood neoplasia

Published: October 15, 2025

Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial.

Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial.

Journal: Clinical lymphoma, myeloma & leukemia

Published: October 10, 2025

Psychometric Evaluation of the Assessment of the Burden of COPD Scale According to the Rasch Model.

Psychometric Evaluation of the Assessment of the Burden of COPD Scale According to the Rasch Model.

Journal: COPD

Published: September 16, 2025

Association Between Transfusion Status, Hemoglobin Levels, and Patient-Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial Analysis.

Association Between Transfusion Status, Hemoglobin Levels, and Patient-Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial Analysis.

Journal: Cancer medicine

Published: September 11, 2025

Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library.

Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library.

Journal: Journal of patient-reported outcomes

Published: September 09, 2025

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.

Journal: Haematologica

Published: August 21, 2025

Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM Trials.

Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM Trials.

Journal: EJHaem

Published: May 16, 2025

SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials.

SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials.

Journal: The Lancet. Oncology

Published: March 30, 2025

Understanding data visualization techniques in qualitative studies used to develop and validate patient-reported outcome measures: a targeted literature review.

Understanding data visualization techniques in qualitative studies used to develop and validate patient-reported outcome measures: a targeted literature review.

Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Published: March 24, 2025

Improvement in Patient-Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO.

Improvement in Patient-Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO.

Journal: European journal of neurology

Published: January 03, 2025

Showing 1-12 of 66

Last Updated: 09/26/2026